Diagnostic Radiopharmaceuticals Contrast Media Market Overview:
The global Diagnostic Radiopharmaceuticals Contrast Media Market size was estimated at USD 14,726.84 million in 2025 and is expected to reach USD 21,343.69 million by 2032, growing at a CAGR of 6.38% from 2025 to 2032. Demand is being propelled by expanding diagnostic imaging volumes across oncology and cardiovascular care, where earlier detection and therapy planning increasingly rely on PET, SPECT, CT, and MRI workflows. Growing investment in modern imaging infrastructure and protocol standardization across large health systems is reinforcing recurring utilization of contrast agents and diagnostic radiopharmaceuticals.
REPORT ATTRIBUTE
DETAILS
Historical Period
2020-2024
Base Year
2025
Forecast Period
2026-2032
Diagnostic Radiopharmaceuticals Contrast Media Market Size 2025
USD 14,726.84 million
Diagnostic Radiopharmaceuticals Contrast Media Market, CAGR
6.38%
Diagnostic Radiopharmaceuticals Contrast Media Market Size 2032
USD 21,343.69 million
Key Market Trends & Insights
The market is projected to expand from USD 14,726.84 million (2025) to USD 21,343.69 million (2032), reflecting a 6.38% CAGR over 2025–2032.
North America accounted for the largest regional share of 40.40% in 2025 due to high imaging procedure density and broad access to advanced modalities.
CT held the leading imaging modality share of 50.90% in 2025, supported by high-throughput diagnostics and emergency care utilization.
Oncology represented the largest indication share of 46.70% in 2025 as staging, response assessment, and surveillance drive repeat imaging.
Hospitals led the end-user mix with a 41.80% share in 2025 because complex care pathways and integrated imaging departments concentrate demand.
Segment Analysis
Diagnostic radiopharmaceuticals and contrast media demand is closely tied to how health systems prioritize early diagnosis and treatment monitoring, particularly in cancer and cardiology pathways where imaging frequency is higher. Product selection is shaped by modality-specific protocols, safety positioning, and operational efficiency, with sites emphasizing predictable workflow, dosing consistency, and compatibility with existing scanners and injector systems. Increased use of molecular imaging is expanding utilization of PET and SPECT tracers, especially where imaging directly informs therapy decisions or patient selection.
Purchasing behavior tends to concentrate around hospital networks and high-volume diagnostic providers that value reliable supply and standardized protocols. Diagnostic centers are strengthening their role as imaging continues shifting toward outpatient settings, and the adoption of modern CT and MRI platforms supports consistent demand for iodinated and gadolinium-based agents. Across product categories, suppliers compete on clinical performance, safety confidence, supply continuity, and ease of integration into established imaging workflows.
By Product Type Insights
Contrast reagents accounted for the largest share of 56.80% in 2025. High CT utilization sustains broad iodinated contrast consumption, particularly in acute care and high-throughput diagnostic pathways. MRI contrast remains supported by protocol-driven use in neuro, oncology, and body imaging where lesion characterization is important. Diagnostic radiopharmaceutical uptake is rising as molecular imaging becomes more embedded in oncology decision-making and patient monitoring workflows.
By Imaging Modality Insights
CT accounted for the largest share of 50.90% in 2025. CT remains a frontline modality for rapid diagnosis and broad clinical coverage, which supports routine contrast utilization. Scan standardization and workflow automation increase throughput, reinforcing repeat demand for contrast products. PET and SPECT utilization is expanding as molecular imaging becomes more central in oncology and cardiology workups and as sites invest in capability upgrades.
By Indication Insights
Oncology accounted for the largest share of 46.70% in 2025. Cancer care increasingly relies on imaging for staging, therapy selection, response assessment, and surveillance, which raises repeat scan volumes. Adoption of molecular imaging supports more precise disease characterization and strengthens tracer utilization in oncology pathways. Continued expansion of advanced imaging capacity and more structured protocols in cancer centers support sustained demand across both radiopharmaceuticals and contrast media.
By Administration Route Insights
Intravenous administration remained the primary route for diagnostic radiopharmaceuticals and most contrast-enhanced CT and MRI procedures because it provides predictable biodistribution and consistent timing for image acquisition. Standardized IV protocols support efficient workflow in high-throughput imaging centers and help align dosing and safety monitoring practices. Oral administration remains important in select gastrointestinal imaging protocols but plays a smaller role in molecular imaging-driven growth.
By End-user Insights
Hospitals accounted for the largest share of 41.80% in 2025. Complex inpatient and emergency imaging volumes, alongside integrated radiology and nuclear medicine departments, concentrate demand in hospital settings. Hospital systems also support advanced imaging pathways that require coordinated scheduling, clinical oversight, and protocol standardization. Diagnostic centers continue to expand capacity as outpatient imaging grows, supporting broader access and rising utilization across community-based care.
Diagnostic Radiopharmaceuticals Contrast Media Market Drivers
Rising burden of complex diseases requiring imaging-led decisions
Growing prevalence of oncology and cardiovascular conditions is increasing reliance on imaging for diagnosis, staging, treatment planning, and follow-up. Protocol-driven CT and MRI usage supports recurring demand for iodinated and gadolinium-based agents in routine and specialized exams. Molecular imaging adoption strengthens the role of PET and SPECT in identifying disease extent and therapy response. Provider emphasis on earlier detection is increasing scan frequency across high-risk cohorts and structured care pathways.
For instance, Lantheus reported that its PSMA-targeted PET imaging agent PYLARIFY supported over 400,000 scans in the U.S. within two years of launch, reflecting rapid clinical uptake in prostate cancer detection and monitoring.
Expansion of advanced imaging infrastructure and capacity
Health systems are modernizing imaging fleets and expanding access to advanced CT, MRI, PET/CT, and hybrid capabilities to reduce wait times and improve diagnostic throughput. Higher scanner density and better scheduling infrastructure support more examinations per site, reinforcing baseline reagent consumption. Outpatient imaging growth is also broadening demand beyond tertiary centers. Investments in capability upgrades further support tracer availability and standardized utilization across oncology and cardiology service lines.
Increasing adoption of molecular imaging and theranostics workflows
The shift toward precision medicine is accelerating use of molecular imaging in oncology and select cardiology and neurology applications. Diagnostic radiopharmaceuticals are increasingly used to inform treatment selection and monitor response, supporting expanding tracer volumes. As more sites integrate molecular imaging into routine practice, demand rises for reliable supply chains and consistent production quality. This trend supports both tracers and complementary cross-sectional imaging that often uses contrast to refine anatomical interpretation.
For instance, Novartis reported treating over 20,000 patients globally with its radioligand therapy Lutathera within a few years of approval, demonstrating the scaling integration of theranostics into clinical oncology workflows.
Operational focus on workflow efficiency and standardized protocols
Radiology and nuclear medicine departments are prioritizing predictable workflows, dosing consistency, and compatibility with installed equipment. Standardized protocols simplify procurement, reduce variability in scan quality, and support routine utilization across large provider networks. As imaging shifts toward higher throughput and outpatient settings, reliable supply and integrated delivery systems become more important. This operational emphasis encourages repeat purchasing and long-term supplier relationships.
Diagnostic Radiopharmaceuticals Contrast Media Market Challenges
Supply continuity and logistics remain persistent challenges, particularly for time-sensitive radiopharmaceuticals that require controlled production, distribution, and scheduling discipline. Any disruption can reduce scan availability and create backlogs, which can affect both patient care and provider economics. Safety perceptions and protocol constraints also influence usage patterns, especially where patients have renal risk factors or where sites tighten governance around contrast administration. Price pressure from procurement consolidation can also constrain margins and intensify competition.
For instance, Curium operates a network of over 50 production and distribution sites globally for SPECT imaging isotopes such as Technetium-99m, which has a short half-life of approximately 6 hours, requiring multiple daily deliveries to hospitals to avoid cancellation of diagnostic scans.
Regulatory complexity and varied clinical guidelines across regions can slow adoption of newer agents and increase the cost and time associated with approvals, labeling updates, and post-market monitoring. Imaging providers may also face infrastructure constraints, including limited PET/SPECT capacity, staffing shortages, and scheduling bottlenecks that reduce the pace of utilization growth. These factors can lead to uneven regional penetration and delayed adoption of advanced protocols outside major urban centers.
Diagnostic Radiopharmaceuticals Contrast Media Market Trends and Opportunities
Dose optimization and safety-forward positioning are shaping product development and provider adoption, with growing emphasis on minimizing exposure while maintaining diagnostic performance. This trend supports opportunity for differentiated formulations, improved dosing workflows, and stronger clinical education around appropriate use. In parallel, imaging providers are increasing investments in modern equipment, which creates pull-through demand for products that integrate seamlessly with newer scanners and standardized injection systems. Suppliers that align with protocol modernization can strengthen long-term utilization.
For instance, GE HealthCare’s Clariscan (gadoteric acid) demonstrated equivalent image quality at a reduced dose of 0.1 mmol/kg while maintaining a macrocyclic structure associated with higher stability, and the company has deployed over 20,000 contrast injector systems globally that integrate with automated dosing protocols, improving workflow consistency and reducing administration variability.
Outpatient migration and expanding diagnostic center networks are creating new demand pockets, particularly where providers prioritize faster access and lower cost per scan. Growth in oncology-focused imaging pathways also supports expanding demand for PET tracers, especially in markets increasing molecular imaging capacity. Opportunities also exist in improving supply chain resilience and delivery reliability, including expanded production footprints and distribution partnerships to meet rising procedure volumes and reduce scheduling disruption risk.
Regional Insights
North America
North America held a 40.40% share in 2025, supported by high imaging procedure density, strong reimbursement structures, and broad access to advanced CT, MRI, and PET capabilities. Large integrated delivery networks promote standardized protocols, which supports consistent utilization of contrast agents and diagnostic radiopharmaceuticals. Concentration of specialized cancer centers and cardiac programs increases demand for imaging-led decision-making and repeat monitoring. Supplier competition in the region emphasizes supply reliability, protocol compatibility, and product differentiation tied to clinical performance and safety confidence.
Europe
Europe accounted for 24.10% in 2025, reflecting mature imaging utilization across major health systems and strong adoption of advanced diagnostic protocols in oncology and neurology. Procurement discipline and structured clinical governance influence product selection and standardization, with emphasis on predictable outcomes and safety considerations. Upgrades in imaging infrastructure and expansion of specialized diagnostic pathways support stable demand across CT, MRI, and nuclear medicine. Suppliers typically compete on clinical confidence, portfolio breadth, and alignment with formulary and protocol requirements across large hospital networks.
Asia Pacific
Asia Pacific represented 26.30% in 2025, driven by expanding imaging capacity, rising chronic disease burden, and increasing access to advanced diagnostics in large population markets. Growth is supported by rapid installation of modern CT and MRI platforms and increasing investment in oncology diagnostics, which expands use of contrast-enhanced imaging. PET and SPECT capacity continues to expand in major urban centers, supporting rising utilization of diagnostic radiopharmaceuticals. Supplier strategies often prioritize distribution reach, pricing adaptability, and partnerships that improve access and service continuity.
Latin America
Latin America captured 5.90% in 2025, shaped by uneven access to advanced imaging infrastructure and variable public health funding across countries. Demand is concentrated in private hospital groups and major metropolitan centers where advanced imaging is more accessible. Import dependence and procurement constraints can affect product availability and pricing stability, influencing utilization consistency. Opportunities are strongest where imaging networks expand outpatient capacity and where cancer diagnostics investments increase procedure volumes.
Middle East & Africa
Middle East & Africa held 3.30% in 2025, with demand concentrated in well-funded health systems and major referral hubs that operate advanced CT, MRI, and selected PET capabilities. Limited nuclear medicine infrastructure in many areas constrains broader radiopharmaceutical penetration outside key centers. Growth is supported by modernization initiatives, increasing medical tourism in select markets, and investment in specialty care pathways. Suppliers often focus on distribution partnerships, service support, and supply reliability to address operational constraints.
Competitive Landscape
The competitive landscape is defined by portfolio breadth, manufacturing and supply reliability, and deep integration into provider workflows. Established players benefit from long-standing hospital relationships, broad distribution networks, and protocol familiarity across imaging departments. Differentiation is increasingly tied to safety positioning, operational efficiency, and the ability to support standardized protocols at scale. Radiopharmaceutical competition is also influenced by production footprint, logistics capability, and alignment with expanding molecular imaging pathways.
GE HealthCare maintains strong positioning through imaging ecosystem alignment across CT, PET, and related workflow infrastructure that supports consistent utilization of diagnostic agents within standardized protocols. The company’s approach typically emphasizes integration with imaging platforms and clinical workflow enablement to improve scan throughput and diagnostic confidence. Capability alignment across hospital networks supports recurring utilization where providers prefer streamlined procurement and consistent imaging protocols. Competitive strength is reinforced when product and workflow priorities match oncology and cardiology imaging growth pathways.
The industry research and growth report includes detailed analyses of the competitive landscape of the market and information about key companies, including:
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key industry players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
Recent Developments
In April 2026, Bracco Imaging announced a strategic alliance with NYU Langone Health through a multi-year Master Research Agreement to advance innovation in MRI, photon-counting CT, targeted ultrasound, and AI-enabled PET/CT and MRI image analysis. In the same announcement, Bracco said the collaboration is intended to accelerate imaging technology development and strengthen precision-medicine decision-making by linking research more closely with clinical practice.
In November 2025, Bracco featured AiMIFY software at RSNA 2025 as its AI-powered contrast enhancement solution for MR imaging in the U.S., offered exclusively with Subtle Medical. Bracco said the software had FDA clearance as a class II medical device and is intended for image enhancement in brain MRI.
In March 2025, Bracco highlighted its collaboration with Zereau BV at ECR 2025 through “The Water Project,” an initiative focused on an advanced urine filtration system designed to address contrast agents in wastewater. Bracco presented this partnership as part of its broader push to improve contrast media efficiency while reducing environmental impact in radiology.
In December 2024, Siemens Healthineers completed its acquisition from Novartis of Advanced Accelerator Applications Molecular Imaging, a European manufacturing and distribution network for PET diagnostic radiopharmaceuticals. Siemens Healthineers said the transaction added 13 manufacturing sites across France, Spain, Portugal, Italy, and Germany, along with product distribution into Switzerland, expanding the reach of its PETNET Solutions business.
1. Introduction
1.1. Report Description
1.2. Purpose of the Report
1.3. USP & Key Offerings
1.4. Key Benefits for Stakeholders
1.5. Target Audience
1.6. Report Scope
1.7. Regional Scope 2. Scope and Methodology
2.1. Objectives of the Study
2.2. Stakeholders
2.3. Data Sources
2.3.1. Primary Sources
2.3.2. Secondary Sources
2.4. Market Estimation
2.4.1. Bottom-Up Approach
2.4.2. Top-Down Approach
2.5. Forecasting Methodology 3. Executive Summary 4. Introduction
4.1. Overview
4.2. Key Industry Trends 5. Global Diagnostic Radiopharmaceuticals Contrast Media Market
5.1. Market Overview
5.2. Market Performance
5.3. Impact of COVID-19
5.4. Market Forecast 6. Market Breakup by Product Type
6.1. Radiopharmaceuticals
6.1.1. Market Trends
6.1.2. Market Forecast
6.1.3. Revenue Share
6.1.4. Revenue Growth Opportunity
6.2. Iodinated Contrast
6.2.1. Market Trends
6.2.2. Market Forecast
6.2.3. Revenue Share
6.2.4. Revenue Growth Opportunity
6.3. Gadolinium-based
6.3.1. Market Trends
6.3.2. Market Forecast
6.3.3. Revenue Share
6.3.4. Revenue Growth Opportunity 7. Market Breakup by Imaging Modality
7.1. CT
7.1.1. Market Trends
7.1.2. Market Forecast
7.1.3. Revenue Share
7.1.4. Revenue Growth Opportunity
7.2. MRI
7.2.1. Market Trends
7.2.2. Market Forecast
7.2.3. Revenue Share
7.2.4. Revenue Growth Opportunity
7.3. PET
7.3.1. Market Trends
7.3.2. Market Forecast
7.3.3. Revenue Share
7.3.4. Revenue Growth Opportunity
7.4. SPECT
7.4.1. Market Trends
7.4.2. Market Forecast
7.4.3. Revenue Share
7.4.4. Revenue Growth Opportunity 8. Market Breakup by Indication
8.1. Oncology
8.1.1. Market Trends
8.1.2. Market Forecast
8.1.3. Revenue Share
8.1.4. Revenue Growth Opportunity
8.2. Cardiology
8.2.1. Market Trends
8.2.2. Market Forecast
8.2.3. Revenue Share
8.2.4. Revenue Growth Opportunity
8.3. Neurology
8.3.1. Market Trends
8.3.2. Market Forecast
8.3.3. Revenue Share
8.3.4. Revenue Growth Opportunity 9. Market Breakup by Administration Route
9.1. IV
9.1.1. Market Trends
9.1.2. Market Forecast
9.1.3. Revenue Share
9.1.4. Revenue Growth Opportunity
9.2. Oral
9.2.1. Market Trends
9.2.2. Market Forecast
9.2.3. Revenue Share
9.2.4. Revenue Growth Opportunity 10. Market Breakup by End-user
10.1. Hospitals
10.1.1. Market Trends
10.1.2. Market Forecast
10.1.3. Revenue Share
10.1.4. Revenue Growth Opportunity
10.2. Diagnostic Centers
10.2.1. Market Trends
10.2.2. Market Forecast
10.2.3. Revenue Share
10.2.4. Revenue Growth Opportunity
10.3. Others
10.3.1. Market Trends
10.3.2. Market Forecast
10.3.3. Revenue Share
10.3.4. Revenue Growth Opportunity 11. Market Breakup by Region
11.1. North America
11.1.1. United States
11.1.1.1. Market Trends
11.1.1.2. Market Forecast
11.1.2. Canada
11.1.2.1. Market Trends
11.1.2.2. Market Forecast
11.1.3. Mexico
11.1.3.1. Market Trends
11.1.3.2. Market Forecast
11.2. Europe
11.2.1. Germany
11.2.2. France
11.2.3. United Kingdom
11.2.4. Italy
11.2.5. Spain
11.2.6. Others
11.3. Asia-Pacific
11.3.1. China
11.3.2. Japan
11.3.3. India
11.3.4. South Korea
11.3.5. Australia
11.3.6. Others
11.4. Latin America
11.4.1. Brazil
11.4.2. Mexico
11.4.3. Others
11.5. Middle East and Africa
11.5.1. Market Trends
11.5.2. Market Breakup by Country
11.5.3. Market Forecast 12. SWOT Analysis
12.1. Overview
12.2. Strengths
12.3. Weaknesses
12.4. Opportunities
12.5. Threats 13. Value Chain Analysis 14. Porter’s Five Forces Analysis
14.1. Overview
14.2. Bargaining Power of Buyers
14.3. Bargaining Power of Suppliers
14.4. Degree of Competition
14.5. Threat of New Entrants
14.6. Threat of Substitutes 15. Price Analysis 16. Competitive Landscape
16.1. Market Structure
16.2. Key Players
16.3. Profiles of Key Players
16.3.1. GE HealthCare
16.3.1.1. Company Overview
16.3.1.2. Product Portfolio
16.3.1.3. Financials
16.3.1.4. SWOT Analysis
16.3.2. Bayer
16.3.3. Bracco
16.3.4. Guerbet
16.3.5. Siemens Healthineers
16.3.6. Lantheus
16.3.7. Curium
16.3.8. Jubilant Radiopharma
16.3.9. Cardinal Health
16.3.10. Fujifilm 17. Research Methodology
Request A Free Sample
We prioritize the confidentiality and security of your data. Our promise: your information remains private.
Ready to Transform Data into Decisions?
Request Your Sample Report and Start Your Journey of Informed Choices
Providing the strategic compass for industry titans.
Frequently Asked Questions:
What is the market size and forecast for the Diagnostic Radiopharmaceuticals Contrast Media Market?
The Diagnostic Radiopharmaceuticals Contrast Media Market was valued at USD 14,726.84 million in 2025. The Diagnostic Radiopharmaceuticals Contrast Media Market is expected to reach USD 21,343.69 million by 2032.
What is the growth rate for the Diagnostic Radiopharmaceuticals Contrast Media Market?
The Diagnostic Radiopharmaceuticals Contrast Media Market is projected to grow at a CAGR of 6.38% during 2025–2032. This growth reflects rising utilization across CT, MRI, PET, and SPECT imaging pathways.
What is the largest segment in the Diagnostic Radiopharmaceuticals Contrast Media Market?
CT is the largest imaging modality segment with a 50.90% share in 2025. CT leadership is supported by high procedure throughput and broad clinical use across acute and routine diagnostics.
What factors are driving growth in the Diagnostic Radiopharmaceuticals Contrast Media Market?
Growth is driven by expanding oncology and cardiology imaging volumes and broader adoption of advanced diagnostic pathways. Increasing infrastructure investment and protocol standardization also support repeat utilization of diagnostic agents.
Which companies are leading in the Diagnostic Radiopharmaceuticals Contrast Media Market?
Key companies include GE HealthCare, Bayer, Bracco, Guerbet, Siemens Healthineers, Lantheus, Curium, Jubilant Radiopharma, Cardinal Health, and Fujifilm. These companies compete through portfolio breadth, supply reliability, and workflow integration.
Which region leads the Diagnostic Radiopharmaceuticals Contrast Media Market?
North America leads the Diagnostic Radiopharmaceuticals Contrast Media Market with a 40.40% share in 2025. Regional leadership is supported by high imaging procedure density and broad access to advanced modalities.
About Author
Shweta Bisht
Healthcare & Biotech Analyst
Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.
The global Desalting And Buffer Exchange Market size was estimated at USD 1,624.38 million in 2025 and is expected to reach USD 2,707.79 million by 2032, growing at a CAGR of 8.89% from 2025 to 2032.
The global Depth Filteration Market size was estimated at USD 2,184.73 million in 2025 and is expected to reach USD 3,507.54 million by 2032, growing at a CAGR of 8.21% from 2025 to 2032.
The global Dental Syringes Market size was estimated at USD 492.73 million in 2025 and is expected to reach USD 658.80 million by 2032, growing at a CAGR of 4.96% from 2025 to 2032.
The global Dental Surgical Instruments Market size was estimated at USD 2,784.61 million in 2025 and is expected to reach USD 3,879.01 million by 2032, growing at a CAGR of 5.68% from 2025 to 2032.
The global Diabetes Care Devices Market size was estimated at USD 29,384.61 million in 2025 and is expected to reach USD 49,607.36 million by 2032, growing at a CAGR of 9.12% from 2025 to 2032.
The global Dental Microscope Market size was estimated at USD 312.48 million in 2025 and is expected to reach USD 493.67 million by 2032, growing at a CAGR of 7.92% from 2025 to 2032.
The global Dental Milling Machine Market size was estimated at USD 896.27 million in 2025 and is expected to reach USD 1,480.93 million by 2032, growing at a CAGR of 8.73% from 2025 to 2032.
The global Dental Digital X-Ray Systems Market size was estimated at USD 2,146.58 million in 2025 and is expected to reach USD 3,484.68 million by 2032, growing at a CAGR of 8.41% from 2025 to 2032.
Dental Liners And Bases Market
The global Dental Liners And Bases Market size was estimated at USD 548.29 million in 2025 and is expected to reach USD 771.62 million by 2032, growing at a CAGR of 5.86% from 2025 to 2032.
The global Dental Infection Control Market size was estimated at USD 1,824.36 million in 2025 and is expected to reach USD 2,705.79 million by 2032, growing at a CAGR of 6.79% from 2025 to 2032.
The global Dental Healing Caps Market size was estimated at USD 386.94 million in 2025 and is expected to reach USD 551.37 million by 2032, growing at a CAGR of 6.08% from 2025 to 2032.
The global Dental Caries Detector Market size was estimated at USD 412.86 million in 2025 and is expected to reach USD 648.99 million by 2032, growing at a CAGR of 7.83% from 2025 to 2032.
Licence Option
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing. Use restricted to one purchaser only.
$3999
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis. Unlimited users allowed within one corporate location (e.g., regional office).
$4999
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc. research team. Permitted for unlimited global use by all users within the purchasing corporation, such as all employees of a single company.
Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.
Materials Scientist (privacy requested)
The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.
